

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/901,429	07/09/2001	David N. Herndon	D6414 7358	
75	90 11/20/2002			
Benjamin Aaron Adler			EXAMINER	
ADLER & ASS 8011 Candle La	ine		KIM, VICKIE Y	
Houston, TX 77071			ART UNIT	PAPER NUMBER
			1614	10
		DATE MAILED: 11/20/2002		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
Advisory Action	09/901,429	HERNDON, DAVID N.			
,	Examiner	Art Unit			
,	Vickie Kim	1614			
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence address			
THE REPLY FILED FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.					
PERIOD FOR RE	PLY [check either a) or b)]				
a) The period for reply expiresmonths from the mailing b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire is ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The	Advisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF TH	g date of the final rejection. IE FINAL REJECTION. See MPEP			
fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the control of the contro	of extension and the corresponding amo the shortened statutory period for reply the later than three months after the mail	unt of the fee. The appropriate extension originally set in the final Office action; or			
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.					
2. The proposed amendment(s) will not be entered because:					
(a) ☐ they raise new issues that would require further consideration and/or search (see NOTE below);					
(b) ☐ they raise the issue of new matter (see Note below);					
(c) ⊠ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or					
(d) they present additional claims without canceling a corresponding number of finally rejected claims.					
NOTE: <u>See Continuation Sheet</u> .					
3. Applicant's reply has overcome the following rejection(s):					
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).					
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because:					
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY t	o issues which were newly			
7. For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.					
The status of the claim(s) is (or will be) as follows:					
Claim(s) allowed:					
Claim(s) objected to:					
Claim(s) rejected:					
Claim(s) withdrawn from consideration:					
8. The proposed drawing correction filed on is	a)□ approved or b)□ disapp	roved by the Examiner.			
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)					
10. Other:					



Continuation of 2. NOTE: The remarks are reconsidered but not persuasive because the claimed subject matter is drawn to a method of treating severly burned patient using the beta-adrenergic antagonist not improving muscle protein metabolism that is found in preamble. As mentioned in the previous office action, the biological pathway is naturally occuring when beta-adrenergic antagonist or propranol is administered to the burned patient and the treatment is accomplished whether the said pathway has involved or not. More precisely, improving muscle protein metabolism is inherently possessed feature whether the said pathway has been known(discovered) in the art or not. Thus, the claims are properly maintained as rejected due to the reasons of the record. As acknowled by the applicant during the restriction requirement practice, a method of treating burn patient and a method of improving muscle protein metabolism(catabolism) are two separate inventions and distinct to each other, this examiner likes to emphasize that the features included in preamble(i.e. improving muscle protein metabolism) is the features that is not the factor to determine the patentability of presecuting instant claims 1-7 and 9-12.

Continuation of 10. Other: